Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Rajesh_Chawla_-_ICU_Protocols_A_stepwise_approa[1].pdf
Скачиваний:
259
Добавлен:
13.03.2016
Размер:
9.49 Mб
Скачать

Sedation and Analgesia

33

 

Ashwin Kumar Mani, Nagarajan Ramakrishnan,

and Sheila Nainan Myatra

A 48-year-old male patient was admitted to the ICU with acute respiratory distress syndrome secondary to H1N1 inßuenza. He was noted to be markedly hypoxemic requiring high FiO2. He was intubated and put on a ventilator. He was tachypneic, tachycardic, and restless and was breathing at the rate of 40 per min and struggling with the ventilator.

Critically ill patients on mechanical ventilation are frequently managed with sedative and analgesics. Pain is a very common experience in the ICU. Failure to recognize pain leads to agitation and increase use of sedatives. Majority of patients Þnd even routine ICU procedures uncomfortable and painful. Inability to communicate about pain due to presence of an endotracheal tube may lead to high levels of anxiety and may precipitate development of posttraumatic stress disorder. Now it is recommended to aggressively manage pain.

Step 1: Identify the need for sedation and analgesia (Table 33.1)

¥Appropriate analgesia might obviate the need for sedation or decrease the sedation needs.

¥In certain groups of patients, sedation is very important to prevent them from selfharm (removing lines) or to decrease the work of breathing and oxygen demand.

¥Common indications of analgesia and sedation (Table 33.1).

A.K. Mani, A.B.(I.M.), A.B.( Pulm. & C.C.M.) (*)

Critical Care Medicine, Apollo First Med Hospital, Chennai, India e-mail: ashwin@icuconsultants.com

N. Ramakrishnan, A.B.(I.M.), F.A.C.P.

Department of Critical Care Services, Apollo Hospitals, Chennai, India

S.N. Myatra, M.D.

Department of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, Mumbai, India

R. Chawla and S. Todi (eds.), ICU Protocols: A stepwise approach,

265

DOI 10.1007/978-81-322-0535-7_33, © Springer India 2012

 

266

A.K. Mani et al.

 

 

Table 33.1 Indications of sedation and analgesia

Facilitation of endotracheal intubation and mechanical ventilation (for amnesia, anxiolysis, reduction of agitation, toleration of endotracheal tube (ETT) and to reduce cough, to alleviate dyspnea, to minimize pain, and to prevent self-extubation)

While performing invasive procedures

To facilitate nursing care

Postoperative/trauma pain

To tolerate ICU environmental inßuences (stressful environment, monitoring devices, noise, fear of illness, separation from family)

During severe hypoxemia (low tidal volume ventilation, high-frequency oscillation (HFO), and prone positioning)

To bear underlying or hospital-acquired medical illnesses

Step 2: Consider the use of commonly used sedatives and analgesics (Table 33.2)

Step 3: Choose an appropriate agent

¥There is no ideal agent for ICU sedation.

¥An ideal sedative and analgesic regimen should provide adequate sedation and pain control, rapid onset of action, and allow rapid recovery after discontinuation, minimal adverse effects, minimal systemic accumulation, and minimal delirium without increasing overall health-care costs.

¥In different clinical scenarios, some agents have been shown to be better than others. Consider the following before choosing an agent:

ÐAll patients need analgesia with or without sedation. Recent studies have shown that minimal use of continuous sedation is feasible without apparent adverse effects.

ÐHave a patient-focused approach. Select analgesic and sedative drugs based on patientsÕ needs.

¥Remember that the degree of sedation/anxiolysis and analgesia required varies between patients and in the same patient over time (physiotherapy, weaning).

¥Identify predisposing and precipitating factorsÑunderlying medical conditions such as chronic pain or arthritis, history of alcohol, or substance abuse. Psychiatric illness can inßuence medication. For example, patients who appear delirious or severely agitated in the ICU may become overmedicated with sedative drugs because their medications have been omitted.

¥Adequate analgesia should be ensured prior to sedating the patient.

¥In a nonintubated patient agitated due to pain, when opioid analgesics such as morphine or fentanyl are used, remember that they can cause respiratory depression. In patients with obstructive sleep apnea, even small doses should be used with caution.

¥For postoperative pain/trauma, epidural analgesia, if available, is a suitable option.

¥Gamma-aminobutyric acid agonists (benzodiazepines, propofol) are prone to cause acute cognitive dysfunction.

Table 33.2 Drug details for sedation and analgesia

 

 

 

 

Time

Duration

Presence

 

 

 

 

to onset

of effect of

of active

Accumulation

 

 

Drug

(min)

one dose (h)

metabolites

in renal failure

Dose (IV)

Comments

Fentanyl

1Ð2

2Ð4

No

No

B+ = 50Ð100 mcg

Reduces tachypnea

 

 

 

 

 

 

Respiratory depression

 

 

 

 

 

I+ = 0.7Ð10 mcg/kg/hr

Accumulation in hepatic/renal failure

Morphine

5Ð10

2Ð4

Yes

Yes

B = 1Ð10 mg

Same as other opioids

 

 

 

 

 

I = 2Ð10 mg/h

 

Remifentanil

1Ð2

10Ð20 mt

No

No

B = 1 mcg/kg

Decreased heart rate and blood pressure

 

 

 

 

 

I = 0.25Ð1.0 mcg/kg/min

Increased intracranial pressure

Hydromorphone

5Ð10

2Ð4

Yes

Yes

B = 0.2Ð0.6 mg

May work in patients tolerant to morphine and

 

 

 

 

 

 

fentanyl, respiratory depression

 

 

 

 

 

I = 0.5Ð3 mg/h

Highly addictive

Lorazepam

5Ð20

6Ð8

No

Yes

B = 2Ð4 mg

Propylene glycol toxicity (anion gap

 

 

 

 

 

 

metabolic acidosis, renal insufÞciency)

 

 

 

 

 

2Ð6 mg q4 to q6

Independent risk factor for delirium

 

 

 

 

 

(duration too long for

 

 

 

 

 

 

effective infusions)

 

Midazolam

2Ð10

1Ð4

Yes

Yes

B = 2Ð5 mg

Many drug interactions

 

 

 

 

 

I = 1Ð20 mg/h

May increase midazolam levels

Propofol

30Ð50 s

3Ð10 (dose

No

InsigniÞcant

B = 0.2Ð2

Hypotension

 

 

dependent)

 

 

mg/kg (maximum 20 mg)

Increased serum triglyceride

 

 

 

 

 

I = 10Ð150 mcg/kg/min

Propofol infusion syndrome (>5 mg/kg/h for

 

 

 

 

 

 

more than 48 h)

Dexmedetomidine

30

4

No

No

B = 1 mg/kg (should be

Sedative, anxiolysis, with analgesic property

 

 

 

 

 

given over 15Ð20 min)

(reduces opioid requirement by >50%)

 

 

 

 

 

I = 0.2Ð0.7 mg/kg/h

Notable adverse event is bradycardia

B+ bolus dose, I+ infusion dose

 

 

 

 

 

Analgesia and Sedation 33

267

268

A.K. Mani et al.

 

 

¥Lorazepam is an independent risk factor for transitioning to delirium.

¥Sedation with dexmedetomidine causes less delirium than with midazolam or propofol.

¥Analgosedation or co-sedationÑoften analgesic medications are added to a sedative infusion (e.g., midazolam and fentanyl) with reduced doses of both agents and in some cases more effective therapy.

Pain (Refer Table 33.3)

Patient comfortable/pain free

Yes

Reassess goal daily

 

Titrate and taper therapy to

 

 

maintaingoal

 

Perform awakening trial

 

 

 

No

Nonintubated Intubated

Provide analgesia for postoperative/trauma/acute illness pain using one of the options below:

Intermittent analgesic boluses of IV fentanyl/ morphine/NSAIDs, etc.

Use PO analgesic if feasible

IV PCA

Epidural (if present)— analgesia with infusion/PCEA of local anesthetic and opioid combination

Rule out/correct reversible causes

Use nonpharmacologic treatment

Optimize the environment

Hemodynamically stable (Step 3)

Fentanyl

Hydromorphone

Morphine

Hemodynamically unstable

Fentanyl

Renal impairment

Fentanyl

Hydromorphone

Fentanyl 50 – 100 mcg bolus f/b 50 mcg/h. Revaluate in 15 minutes.

If inadequate pain relief rebolus 50 – 100 mcg and increase drip by 50%.

Revaluate again in 30 minutes and increase or decrease dose by 50% if inadequate or over sedation

Pain scores

Target CPOT=0–1 Numeric PS=3 (mild pain)

33 Sedation and Analgesia

269

 

 

Sedation (Refer Table 33.4, 33.5, 33.6)

 

 

 

 

 

 

 

Anticipate sedation

 

 

 

(<72 hours)

 

 

 

Midazolam

 

Is patient

 

Propofol

 

 

Dexmedetomidine

 

agitated /

 

 

 

 

 

 

 

 

 

 

anxious?

 

 

 

 

 

 

 

 

 

 

Anticipate sedation

 

 

(>72 hours)

 

 

Midazolam

 

 

Lorazepam

 

 

(Concerns of delirium

 

 

 

 

with long-term

 

 

infusions)

 

 

The patient has renal

 

 

impairment

 

 

Lorazepam

 

 

Propofol

 

 

Consider

 

 

 

intermittent boluses

• Propofol 10–25 mcg/kg/min titrated in increments of 10– 25mcg/kg/min every 5–10 minutes till desired level

• Use sedationscales.

• Consider dexmedetomidine 1mcg/kg followed by 0.2–0.7 mcg/kg/h

• Lorazepam bolus 2 mg followed by infusion 1 mg/h

Sedation score (opt any one score)

Target

RASS=0 to –3 (Alert, calm, moderate sedation, movement or eye opening; no eye contact)

SAS=3–4 (Sedated, difficult to arouse but awakens to verbal stimuli or gentle shaking)

Ramsay=3 (Responds only to verbal commands)

Delirium

Pharmacological

treatment

Is patient delirious?

Nonpharmacological

treatment

Dexmedetomidine 0.2–1.5 mcg/kg/h (Consider in patients failing spontaneous breathing trials secondary to agitation)

Haloperidol 2.5–5 mg IV q 15 minutes till delirium present (suggested maximum35 mg/day) (Consider decreased dose in hypoactive delirium)

Haloperidol 2.5–5 mg PO q 6 hours (Caution if baseline QTc > 440 ms)

Quetiapine 50–200 mg PO q 12 hours (Consider if sedative properties desired)

Risperidone 0.5–1 mg PO q 12 hours (Caution baseline QTc > 440 ms)

Daily awakening trials

Reorient patient regularly

Early mobilization

Promote effective sleep/awake cycles

Timely removal of catheters/physical restraints

Use of eyeglasses, magnifying lenses, and hearing aids

Minimize noise/stimulation at night

Minimize benzodiazepines for sedation

270

 

A.K. Mani et al.

 

 

Table 33.3 The critical care pain observation tool (CPOT) (target 0 to 1)

 

Facial expression

Tense

1

 

Grimacing

2

Body movements

Absence of movement or normal position

0

 

Protection

1

 

Restlessness

2

Compliance with ventilator

Tolerating the ventilator or movement

0

(intubated patients)

Coughing but tolerating

1

 

Fighting the ventilator

2

Vocalization (extubated patients)

Talking in normal tone or no sound

0

 

Sighing or moaning

1

 

Crying out, sobbing

2

Muscle tension

Relaxed

0

 

Tense, rigid

1

 

Very tense or rigid

2

Fig. 33.1 Wong-Baker FACES pain rating scale

Step 4: Assessment of pain, sedation, and delirium

¥Use of sedation and pain scales is recommended to titrate the appropriate level of analgesia and sedation.

¥There are many scores, but one score should be followed for uniformity in the ICU.

¥The following scales/scores may be used: A. Pain

¥A critical care pain observation tool (Table 33.3)

¥Self-reporting of pain

¥Wong-Baker FACES pain rating scale (Fig. 33.1)

¥0Ð10 numeric pain scales

33 Sedation and Analgesia

 

271

 

 

Table 33.4 Richmond agitation-sedation scale (RASS) (target 0 to −3)

 

Combative, violent, danger to staff

+4

Pulls or removes tubes or catheters, aggressive

+3

Frequent nonpurposeful movement, Þghts the ventilator

+2

Anxious, apprehensive, but not aggressive

+1

Alert and calm

 

0

Awakens to voice (eye opening/contact) >10 s

−1

Light sedation, brießy awakens to voice (eye opening/contact) <10 s

−2

Moderate sedation, movement or eye opening (no eye contact)

−3

Deep sedation, no response to voice, but movement or eye opening to physical stimulation

−4

Unarousable, no response to voice or physical stimulation

−5

Table 33.5 Riker sedation-agitation scale (SAS) (target sedation 3 to 4)

 

Dangerous agitation, pulling the ETT, trying to remove catheters, climbing over bedrail,

7

striking at staff, thrashing side to side

 

Very agitated, requiring restraint and frequent verbal reminding of limits, biting the ETT

6

Agitated, anxious or physically agitated, calms to verbal instructions

5

Calm and cooperative easily arousable, follows commands

4

Sedated, difÞcult to arouse but awakens to verbal stimuli or gentle shaking, follows simple

3

commands but drifts off again

 

 

Very sedated, arouses to physical stimuli but does not communicate or follow commands,

2

may move spontaneously

 

 

Unarousable, minimal or no response to noxious stimuli, does not communicate or follow

1

commands

 

 

Table 33.6 Ramsay sedation score (target sedation 3)

 

Level/score

Clinical description

 

1Anxious and agitated

2Cooperative, oriented, tranquil

3Responds only to verbal commands

4Asleep with brisk response to light stimulation

5Asleep with sluggish response to stimulation

6Asleep without response to stimulation

B.Sedation

¥Richmond agitation-sedation scale (RASS) (Table 33.4)

¥Riker sedation-agitation scale (SAS) (Table 33.5)

¥Ramsay sedation score (Table 33.6)

C.Delirium

¥Confusion assessment method for the ICU

¥The intensive care delirium screening checklist

Step 5: Titrate sedation and analgesia

The titration of the sedative/analgesic dose to a deÞned endpoint is recommended.

272

A.K. Mani et al.

 

 

Titrating infusions

Analgesia

The potential for opioid withdrawal should be considered for patients receiving high doses or 7 days of continuous therapy. Doses should be tapered systematically (i.e., 10Ð30% per day) to prevent withdrawal symptoms.

Sedation

Use RASS/SAS/Ramsay scores to evaluate. Titrate according to the target table.

¥Lorazepam/midazolam continuous infusion: Hold infusion until the patient reaches RASS goal, and then resume at one-half the previous rate. Titrate as per written orders.

¥Propofol continuous infusion: Decrease at the rate of 5Ð10 mcg/kg/min every 10 min until the patient reaches RASS goal. Titrate as per written orders.

¥Morphine/fentanyl continuous infusion: Hold until the patient reaches RASS goal, and then resume at one-half the previous rate. Titrate as per written orders.

Step 6: Daily awakening trial

¥Daily awakening trial is required to assess sedation and minimum effective dose for sedation.

¥It is recommended to couple spontaneous breathing trial (SBT) protocols with sedation protocols. Findings show that combined approach of spontaneous breathing trial and daily awakening results in less time on mechanical ventilation and less intensive care and the hospital stay.

¥Early exercise and mobilization (physical and occupational therapy) during periods of daily interruption of sedation has been shown to be safe and well tolerated and results in better functional outcomes at hospital discharge, a shorter duration of delirium, and more ventilator-free days compared with standard care.

Assess for daily awakening Exclusions:

Increased intracranial pressure

Neuromuscular blockade

Very high PEEP, FiO2

CABG-immediate post-op

Perform daily Awakening

Wean/stop sedation

Consider decreasing narcotics infusion by 25-50%

Is patient awake and calm?

Use sedation scale

SAS 3–4 (sedated, difficult to arouse but awakens to verbal stimuli or gentle shaking, follows simple commands) or RASS 0 to – 1(alert and calm, awakens to voice (eye opening/contact) >10 seconds)

Yes

Spontaneous breathing trial

No

Restart sedation at previous dose (no rapid shallow breathing index)

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]